Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (July 2005)
22 slides from Genetic Technologies's investor presentation, Jul 28, 2005
Slide 1: Science and Sales: Bringing Inventions to the Market
genefic technologies : # _ SCIENCEAND SALES)” : = Bringing Inventions to the Market. | ~Executive.Chairman >: “Genetic Technologies Limited
Slide 2: From an Acorn to an Oak
Genetic Technologies —_. hd , - From an Acorn to an Oak Hh locas = Founded 1989, ASX listed 2000, Listing on NASDAQ 2005 Original research focussed on structure of genes This led to broad patents on the use of non- -codin DNA . This provided basis for a new licensing business - GTG created a DNA ser
Slide 3: The Potential of the Global Biotech Market is Vast
The Potential of the Global ji - Biotech Market | is Vast TE rd ‘Huge boost from the Human Genome Program « Treatment concepts - from. pills to genetic “wands” - Not just human medicine — animals, plants, energy etc ~ _ Global View oe —-USA pharma is spending $3-6B pao on genomics research ; —- Colo
Slide 4: Motivation to do Research
“Motivation to do Research bi Old days: : publicly funded institutes - driven by purported altruism + -companies.- make. money. ae +. therefore - the old view - institutes make inventions and companies take “them to the market. : ; ; : . These days: : : «institutes are under pressure to become self-
Slide 5: Additional Pressures on the Institutes
Institutes _ = Me ' “Altruism and the original mission of the institutes — ~* Particular interest in certain projects, diseases, challenges 8 ‘Pressure to maintain status, prestige, power, need to ~~. publish, « Plus = : oe — the need to move towards becoming self-supporting financially. ~. need to
Slide 6: Research leads to Inventions, Patents, Licenses, Revenues
~ Research leads to Inventions — Inventions lead to Patents Patents lead to Licenses Licenses lead to Revenues Revenues lead to more Research
Slide 7: A Further Complication
ic techndlogies ~ A Further Complication ene . There are now v three different cultures involved, each with their own language: : = Science ~The Patenting Process. = Exploiting Business Opportunities The challenge is to find people who can bridge these cultures.
Slide 8: Patenting, Copyrighting and Other Registrations
-Patenting. Copyrighting Other registrations - trade marks etc Trade secrets. See ~The need for confi identiality
Slide 9: Taking Inventions to the Market
Taking Inventions tothe Ai What is actually being sold?” “ea concept, often at an early stage, maybe even before Proof of. Principle, * an invention - ‘proven it in lab, ‘but maybe no patent has yet. issued. oa patent. : oa license to the patent - innumerable variations - = exclusive or non-exclusiv
Slide 10: Protecting Inventions by the Patent Process
Protecting Inventions by the Patent process | rie ‘ Intended by Governments to encourage innovation, - enterprise & persistence. —— + Reward is a valuable legal monopoly albeit for. a small ~ ~~ number of years. : oe There is no prize for second best. ~* Governments have established global conventio
Slide 11: Some Risks of Relying on the Patent Process
Some Risks of Relying o on- hy ; the Patent Process _ | hi ledges - The original hypothesis may be proven to be wrong. The hypothesis may be proven to. be right - but» unpatentable. . A patent may be granted, but there i is no clear way to make money. me A patent may be granted, but some other inven
Slide 12: Famous Quotes
genetic techndlogies Se Famous Quotes - ihe _—e “Why should we 2 all have to. pay for 0 one company s bright | . ideas: ?. - = New Scientist May 2002
Slide 13: Famous Quotes
fic techndlogies 7 Famous Quotes | ot _ + “Those patents are > immoral — of course, I’ve never read _ them myself” oe are a _. Professor at New Zealand University
Slide 14: Gene patents: Pathologists call on Governments to challenge GTG
=e “Gene patents: Pathologists call. on Governments to . ‘challenge ¢ GTG”. ~ - Australian Biotechnology News, May 2003 ;
Slide 15: Famous Quotes
Famous Quotes Ae | “DNA has two types of digital information = ‘the genes ofthat in code proteins and the gene regulatory networks” “The digital code of DNA" by Leroy Hood and David Galas, “Nature”, ; January 2003.
Slide 16: How come we never saw that before?
- “How come we never saw that before?” : Famous Quotes : Ln] - Director of Science at Affymetrix, a major US biotech company. -
Slide 17: My goodness, there's a lot more that matters in the human genome
ve “My goodness, there’ s.a lot more that matters in the human. : genome than we had realised”. . . - Dr Eric Lander, Director of Genome Research, Whitehead Institute, USA SS
Slide 18: Famous Quote
_ Famous Quote aS az . “The failure of biologists to consider the massive amounts of transcription involving non-coding DNA and. ~-the.Genome will be regarded as perhaps the biggest mistake i in the history of biology’. : ~. - Professor John Mattick, February 2003.
Slide 19: Pathologists back down from GTG attack
os “Pathologists back down from GTG attack”, a ‘Australian Biotechnology News July 2003.
Slide 20: An Optimal Strategy for a Small Company Licensing Rollout
An Optimal Strategy for a Small nin - ~ Company Licensing Rollout a -. Get listed ona public exchange — for clout + Secure patent insurance — if you can : ~« Builda database of prospective targets -« Understand your targets — produce claim charts 8 ‘Engage them in negotiations —the carrot and the st
Slide 21: Segment your Market
ic techndlogies : : Segment your Market bd All Companies ¢ are not equal : = . Small — maybe not worth too much effort initially. ~* Medium — focussed on their mission, short chain of command and generally good value to work with a -* Large — typically confused, unsure who has responsibility and dif
Slide 22: Forbes Magazine 2003
“FORBES MAGAZINE 2003
Genetic Technologies — Investor Presentation (July 2005) on 6ix